(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Creative Realities, Palantir, and Marathon.

The three biggest losers today are Sorrento Therapeutics, Geo Group, and Coda Octopus Group.

Winners today

1. Creative Realities (CREXW) – 62.5%

NASDAQ ended the session with Creative Realities jumping 62.5% to $0.02 on Tuesday while NASDAQ jumped 0.57% to $11,960.15.

Yearly Top and Bottom Value

Creative Realities’s stock is valued at $0.02 at 16:32 EST, above its 52-week high of $0.02.

More news about Creative Realities.

2. Palantir (PLTR) – 21.48%

Palantir Technologies Inc. builds and deploys software platforms for the intelligence community in the United States to assist in counterterrorism investigations and operations. The company provides palantir gotham, a software platform which enables users to identify patterns hidden deep within datasets, ranging from signals intelligence sources to reports from confidential informants, as well as facilitates the handoff between analysts and operational users, helping operators plan and execute real-world responses to threats that have been identified within the platform. It also offers palantir foundry, a platform that transforms the ways organizations operate by creating a central operating system for their data; and allows individual users to integrate and analyze the data they need in one place. In addition, it provides apollo, a software that enables customers to deploy their own software virtually in any environment. Palantir Technologies Inc. was incorporated in 2003 and is based in Denver, Colorado.

NYSE ended the session with Palantir rising 21.48% to $9.24 on Tuesday, after two successive sessions in a row of gains. NYSE dropped 0.01% to $16,050.10, after two successive sessions in a row of gains, on what was a somewhat negative trend exchanging session today.

Palantir stock earnings: PLTR shoots up 23% on profitability, but citi warns on revenueKarp did not specify the GAAP figure but said Palantir would achieve between $481 and $531 million in adjusted income from operations for 2023., What is more, and by far more important, is that Palantir CEO Alex Karp told analysts to expect a real but small profit for the full year of 2023.

Stocks making the biggest moves midday: palantir, NVIDIA, avis budget and moreThe action comes a day after Palantir reported it made a profit in the fourth quarter, its first quarter of positive GAAP income, at $31 million.

Earnings Per Share

As for profitability, Palantir has a trailing twelve months EPS of $-0.28.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -23.89%.

Moving Average

Palantir’s value is above its 50-day moving average of $8.86 and way below its 200-day moving average of $11.44.

Volatility

Palantir’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.84%, a positive 0.44%, and a positive 2.99%.

Palantir’s highest amplitude of average volatility was 3.22% (last week), 3.65% (last month), and 2.99% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Palantir’s stock is considered to be overbought (>=80).

Yearly Top and Bottom Value

Palantir’s stock is valued at $9.24 at 16:32 EST, way below its 52-week high of $28.38 and way above its 52-week low of $6.44.

Previous days news about Palantir

• Stocks making the biggest moves after hours: avis, palantir, cadence design and more. According to CNBC on Monday, 13 February, "It is also the first quarter Palantir posted positive net income on a GAAP basis, coming in at $31 million."

More news about Palantir.

3. Marathon (MARA) – 15.3%

Marathon Digital Holdings, Inc. operates as a digital asset technology company that mines cryptocurrencies with a focus on the blockchain ecosystem and the generation of digital assets in United States. As of December 31, 2021, it had approximately 8,115 bitcoins, which included the 4,794 bitcoins held in the investment fund. The company was formerly known as Marathon Patent Group, Inc. and changed its name to Marathon Digital Holdings, Inc. in February 2021. Marathon Digital Holdings, Inc. was incorporated in 2010 and is headquartered in Las Vegas, Nevada.

NASDAQ ended the session with Marathon jumping 15.3% to $6.74 on Tuesday, after four consecutive sessions in a row of losses. NASDAQ rose 0.57% to $11,960.15, following the last session’s upward trend on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, Marathon has a trailing twelve months EPS of $-0.13.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -34.72%.

Yearly Top and Bottom Value

Marathon’s stock is valued at $6.74 at 16:32 EST, way below its 52-week high of $32.74 and way higher than its 52-week low of $3.11.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is a negative 59.1% and a negative 250%, respectively.

More news about Marathon.

4. DiaMedica Therapeutics (DMAC) – 9.35%

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

NASDAQ ended the session with DiaMedica Therapeutics rising 9.35% to $1.52 on Tuesday, following the last session’s upward trend. NASDAQ jumped 0.57% to $11,960.15, following the last session’s upward trend on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, DiaMedica Therapeutics has a trailing twelve months EPS of $-0.784.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -46.74%.

More news about DiaMedica Therapeutics.

5. MicroStrategy (MSTR) – 9.17%

MicroStrategy Incorporated provides enterprise analytics software and services worldwide. It offers MicroStrategy, an enterprise platform, which provides a modern analytics experience by delivering insights across multiple devices to users via hyperintelligence products, visualization and reporting capabilities, mobility features, and custom applications developed on the platform; analysts and data scientists with seamless access to trusted, governed data directly within their tools; and APIs and gateways, multiple deployment options, enterprise semantic graph, scalability, and security. The company also provides MicroStrategy Support that helps customers to achieve their system availability and uptime goals, and to improve the overall experience through highly responsive troubleshooting and proactive technical product support. In addition, it offers MicroStrategy Consulting that provides customers with architecture and implementation services to help them quickly realize results, and helps to achieve returns on investment derived from understanding of data; and MicroStrategy Education that offers free and paid learning options. The company provides its services through enterprise sales force and channel partners. It serves companies from a range of industries, including retail, consulting, technology, manufacturing, finance, banking, insurance, healthcare, education, and telecommunications, as well as the public sector. The company was incorporated in 1989 and is headquartered in Tysons Corner, Virginia.

NASDAQ ended the session with MicroStrategy jumping 9.17% to $272.11 on Tuesday, following the last session’s upward trend. NASDAQ jumped 0.57% to $11,960.15, following the last session’s upward trend on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, MicroStrategy has a trailing twelve months EPS of $-12.31.

Volume

Today’s last reported volume for MicroStrategy is 647116 which is 12.1% above its average volume of 577247.

More news about MicroStrategy.

6. Domo (DOMO) – 8.45%

Domo, Inc. operates a cloud-based platform in the United States. Its platform digitally connects from the chief executive officer to the frontline employee with the people, data, and systems in an organization, giving them access to real-time data and insights, and allowing them to manage business from smartphones. The company was formerly known as Domo Technologies, Inc. and changed its name to Domo, Inc. in December 2011. Domo, Inc. was incorporated in 2010 and is headquartered in American Fork, Utah.

NASDAQ ended the session with Domo jumping 8.45% to $15.66 on Tuesday while NASDAQ rose 0.57% to $11,960.15.

Earnings Per Share

As for profitability, Domo has a trailing twelve months EPS of $-2.89.

More news about Domo.

7. Riot Blockchain (RIOT) – 8.41%

Riot Blockchain, Inc., together with its subsidiaries, focuses on bitcoin mining operations in North America. It operates through Bitcoin Mining, Data Center Hosting, and Electrical Products and Engineering segments. As of December 31, 2021, it operated approximately 30,907 miners. Riot Blockchain, Inc. was incorporated in 2000 and is headquartered in Castle Rock, Colorado.

NASDAQ ended the session with Riot Blockchain jumping 8.41% to $5.93 on Tuesday while NASDAQ rose 0.57% to $11,960.15.

Earnings Per Share

As for profitability, Riot Blockchain has a trailing twelve months EPS of $-0.3.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -36.5%.

Sales Growth

Riot Blockchain’s sales growth for the next quarter is negative 5.6%.

Yearly Top and Bottom Value

Riot Blockchain’s stock is valued at $5.93 at 16:32 EST, way below its 52-week high of $23.66 and way above its 52-week low of $3.25.

Moving Average

Riot Blockchain’s value is way higher than its 50-day moving average of $4.85 and under its 200-day moving average of $6.40.

More news about Riot Blockchain.

8. WESCO (WCC) – 8.26%

WESCO International, Inc. provides business-to-business distribution, logistics services, and supply chain solutions in the United States, Canada, and internationally. It operates through three segments: Electrical & Electronic Solutions (EES), Communications & Security Solutions (CSS), and Utility and Broadband Solutions (UBS). The EES segment supplies products and supply chain solutions, including electrical equipment and supplies, automation and connected devices, security, lighting, wire and cable, and safety, as well as maintenance, repair, and operating (MRO) products. This segment also offers contractor solutions, direct and indirect manufacturing supply chain optimization programs, lighting and renewables advisory services, and digital and automation solutions. The CSS segment operates in the network infrastructure and security markets. This segment sells products directly to end-users or through various channels, including data communications contractors, security, network, professional audio/visual, and systems integrators. It also provides safety and energy management solutions. The UBS segment offers products and services to investor-owned utilities; public power companies; and service and wireless providers, broadband operators, and contractors. This segment's products include wire and cable, transformers, transmission and distribution hardware, switches, protective devices, connectors, conduits, pole line hardware, racks, cabinets, safety and MRO products, and point-to-point wireless devices. This segment also offers various service solutions, including fiber project management, high and medium voltage project design and support, pre-wired meters and capacitor banks, meter testing and metering infrastructure installation, personal protective equipment dielectric testing, and tool repair, as well as emergency response, storage yard, materials, and logistics management. The company was founded in 1922 and is headquartered in Pittsburgh, Pennsylvania.

NYSE ended the session with WESCO jumping 8.26% to $165.83 on Tuesday, after two successive sessions in a row of gains. NYSE slid 0.01% to $16,050.10, after two consecutive sessions in a row of gains, on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, WESCO has a trailing twelve months EPS of $1.51.

PE Ratio

WESCO has a trailing twelve months price to earnings ratio of 109.82. Meaning, the purchaser of the share is investing $109.82 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.99%.

Sales Growth

WESCO’s sales growth is 20.6% for the ongoing quarter and 12.3% for the next.

Volume

Today’s last reported volume for WESCO is 1120110 which is 173.81% above its average volume of 409068.

Revenue Growth

Year-on-year quarterly revenue growth grew by 22%, now sitting on 19.11B for the twelve trailing months.

More news about WESCO.

9. Tesla (TSLA) – 7.67%

Tesla, Inc. designs, develops, manufactures, leases, and sells electric vehicles, and energy generation and storage systems in the United States, China, and internationally. It operates in two segments, Automotive, and Energy Generation and Storage. The Automotive segment offers electric vehicles, as well as sells automotive regulatory credits; and non-warranty after-sales vehicle, used vehicles, retail merchandise, and vehicle insurance services. This segment also provides sedans and sport utility vehicles through direct and used vehicle sales, a network of Tesla Superchargers, and in-app upgrades; purchase financing and leasing services; services for electric vehicles through its company-owned service locations and Tesla mobile service technicians; and vehicle limited warranties and extended service plans. The Energy Generation and Storage segment engages in the design, manufacture, installation, sale, and leasing of solar energy generation and energy storage products, and related services to residential, commercial, and industrial customers and utilities through its website, stores, and galleries, as well as through a network of channel partners; and provision of service and repairs to its energy product customers, including under warranty, as well as various financing options to its solar customers. The company was formerly known as Tesla Motors, Inc. and changed its name to Tesla, Inc. in February 2017. Tesla, Inc. was incorporated in 2003 and is headquartered in Austin, Texas.

NASDAQ ended the session with Tesla jumping 7.67% to $209.56 on Tuesday, after two successive sessions in a row of losses. NASDAQ jumped 0.57% to $11,960.15, following the last session’s upward trend on what was a somewhat positive trend exchanging session today.

: some Tesla workers are pushing to unionize: reportSome Tesla Inc. workers are looking to unionize as they push for pay increases and less corporate monitoring, according to Bloomberg News.

Tesla stock price and forecast: TSLA stock dips on lower CPI but raises price of model Y againWorkers United, an affiliate union of the more powerful Service Employees International Union (SEIU), is campaigning for higher job security at the Buffalo plant where Tesla produces its solar shingle products., On the automotive front, Tesla is altering its pricing on various models for the fourth time this year, this time in the US.

Earnings Per Share

As for profitability, Tesla has a trailing twelve months EPS of $1.

PE Ratio

Tesla has a trailing twelve months price to earnings ratio of 209.98. Meaning, the purchaser of the share is investing $209.98 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 32.49%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 37.2%, now sitting on 81.46B for the twelve trailing months.

More news about Tesla.

10. Cadence Design Systems (CDNS) – 7.36%

Cadence Design Systems, Inc. provides software, hardware, services, and reusable integrated circuit (IC) design blocks worldwide. The company offers functional verification services, including emulation and prototyping hardware. Its functional verification offering consists of JasperGold, a formal verification platform; Xcelium, a parallel logic simulation platform; Palladium, an enterprise emulation platform; and Protium, a prototyping platform for chip verification. The company also provides digital IC design and sign off products, including Genus logic synthesis and Joules RTL power solutions, as well as Modus software solution to reduce systems-on-chip design-for-test time; physical implementation tools, such as place and route, optimization, and multiple patterning preparation; and signoff products to signoff the design as ready for silicon manufacturing. In addition, it offers custom IC design and simulation products to create schematic and physical representations of circuits down to the transistor level for analog, mixed-signal, custom digital, memory, and radio frequency designs; and system design and analysis products to develop printed circuit boards and IC packages, as well as to analyze electromagnetic, electro-thermal, and other multi-physics effects. Further, the company provides intellectual property (IP) products comprising pre-verified and customizable functional blocks to integrate into customer's ICs; and verification IP and memory models to emulate and model the expected behavior and interaction of standard industry system interface protocols. Additionally, it offers services related to methodology, education, and hosted design solutions, as well as technical support and maintenance services. The company serves 5G communications, aerospace and defense, automotive, industrial and healthcare, mobile, consumer, and hyperscale computing markets. Cadence Design Systems, Inc. was incorporated in 1987 and is headquartered in San Jose, California.

NASDAQ ended the session with Cadence Design Systems rising 7.36% to $199.37 on Tuesday while NASDAQ rose 0.57% to $11,960.15.

Earnings Per Share

As for profitability, Cadence Design Systems has a trailing twelve months EPS of $2.34.

PE Ratio

Cadence Design Systems has a trailing twelve months price to earnings ratio of 85.2. Meaning, the purchaser of the share is investing $85.2 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.41%.

More news about Cadence Design Systems.

Losers Today

1. Sorrento Therapeutics (SRNE) – -22.67%

Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 94 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California.

NASDAQ ended the session with Sorrento Therapeutics falling 22.67% to $0.20 on Tuesday while NASDAQ rose 0.57% to $11,960.15.

Earnings Per Share

As for profitability, Sorrento Therapeutics has a trailing twelve months EPS of $-1.3.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -326.72%.

Moving Average

Sorrento Therapeutics’s worth is way below its 50-day moving average of $1.07 and way below its 200-day moving average of $1.68.

More news about Sorrento Therapeutics.

2. Geo Group (GEO) – -16.03%

The GEO Group, Inc. (NYSE: GEO) is a leading diversified government service provider, specializing in design, financing, development, and support services for secure facilities, processing centers, and community reentry centers in the United States, Australia, South Africa, and the United Kingdom. GEO's diversified services include enhanced in-custody rehabilitation and post-release support through the award-winning GEO Continuum of Care, secure transportation, electronic monitoring, community-based programs, and correctional health and mental health care. GEO's worldwide operations include the ownership and/or delivery of support services for 102 facilities totaling approximately 82,000 beds, including idle facilities and projects under development, with a workforce of up to approximately 18,000 employees.

NYSE ended the session with Geo Group sliding 16.03% to $10.03 on Tuesday while NYSE dropped 0.01% to $16,050.10.

Earnings Per Share

As for profitability, Geo Group has a trailing twelve months EPS of $0.94.

PE Ratio

Geo Group has a trailing twelve months price to earnings ratio of 10.68. Meaning, the purchaser of the share is investing $10.68 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.55%.

More news about Geo Group.

3. Coda Octopus Group (CODA) – -12.76%

Coda Octopus Group, Inc., together with its subsidiaries, develops and sells underwater technologies and equipment for imaging, mapping, defense, and survey applications in the Americas, Europe, Australia, Asia, the Middle East, and Africa. The company operates through two segments, Marine Engineering Business and Marine Technology Business. It offers CodaOctopus GeoSurvey data acquisition and interpretation software; acquisition products, such as hardware and software solutions for field acquisition of sidescan sonar and sub-bottom profiler; and CodaOctopus GeoSurvey productivity suite of software that automates the tasks of analyzing, annotating, and mosaicing complex data sets. The company also provides motion sensing products, which include Octopus F180 and F170 products that bring accurate positioning and motion data into offshore conditions for marine survey applications. In addition, it offers CodaOctopus underwater inspection system; 3D MATT, a multiple automatic target tracking solution used for diver tracking; and Echoscope and construction monitoring software used for tracking and placement of single layer armor blocks used in breakwater construction; and 4G Underwater Survey Explorer that provides real-time visualization and automation processing for sonar software. Further, the company provides engineering services and embedded solutions, such as mission computers to prime defense contractors; and Thermite rugged visual computers, subsea telemetry and data acquisition systems, rugged workstations, analog-to-digital converters, and rugged LCD displays. It markets its products under the CodaOctopus brand name. Coda Octopus Group, Inc. was founded in 1994 and is headquartered in Orlando, Florida.

NASDAQ ended the session with Coda Octopus Group dropping 12.76% to $6.60 on Tuesday, after four consecutive sessions in a row of losses. NASDAQ rose 0.57% to $11,960.15, following the last session’s upward trend on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, Coda Octopus Group has a trailing twelve months EPS of $0.38.

PE Ratio

Coda Octopus Group has a trailing twelve months price to earnings ratio of 17.37. Meaning, the purchaser of the share is investing $17.37 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.19%.

Sales Growth

Coda Octopus Group’s sales growth is negative 4.2% for the present quarter and 16.1% for the next.

More news about Coda Octopus Group.

4. Corbus Pharmaceuticals Holdings (CRBP) – -11.06%

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. Its lead product candidate is lenabasum, a cannabinoid receptor type 2 (CB2) that is in Phase III clinical trial for the treatment of dermatomyositis; and in Phase II clinical trial to treat systemic lupus erythematosus. The company is also developing cannabinoid receptor type 1 inverse agonist program for treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; and CB2 agonist program for the treatment of cancer. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

NASDAQ ended the session with Corbus Pharmaceuticals Holdings sliding 11.06% to $0.14 on Tuesday, after three sequential sessions in a row of losses. NASDAQ jumped 0.57% to $11,960.15, following the last session’s upward trend on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, Corbus Pharmaceuticals Holdings has a trailing twelve months EPS of $-0.312.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -69.8%.

Yearly Top and Bottom Value

Corbus Pharmaceuticals Holdings’s stock is valued at $0.14 at 16:32 EST, way under its 52-week high of $0.62 and way higher than its 52-week low of $0.10.

Volume

Today’s last reported volume for Corbus Pharmaceuticals Holdings is 2396420 which is 42.72% below its average volume of 4184280.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Corbus Pharmaceuticals Holdings’s EBITDA is 3.45.

Moving Average

Corbus Pharmaceuticals Holdings’s value is above its 50-day moving average of $0.14 and way under its 200-day moving average of $0.20.

More news about Corbus Pharmaceuticals Holdings.

5. Calyxt (CLXT) – -10.69%

Calyxt, Inc., a technology company, focuses on delivering plant-based solutions in the United States. It engages in the development of improved digestibility alfalfa; high fiber wheat; high oleic low linolenic soybeans; winter oats; hemp; fat soybeans; and cold storable potatoes. As of March 4, 2021, the company had nine projects at Phase I stage or later in development across alfalfa, hemp, oats, soybeans, and wheat. Calyxt, Inc. has a research collaboration with NRGene, which includes the adoption of NRGene's cloud-based genomics platform to support various research projects; and a commercialization agreement with S&W Seed Company for the exclusive license of an improved quality alfalfa seed in the United States and various geographies outside the United States. It also has a strategic alliance with J.R. Simplot Company to drive new breeding techniques for strawberries, including gene editing. The company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. Calyxt, Inc. was incorporated in 2010 and is headquartered in Roseville, Minnesota. Calyxt, Inc. is a subsidiary of Cellectis S.A.

NASDAQ ended the session with Calyxt sliding 10.69% to $0.32 on Tuesday while NASDAQ rose 0.57% to $11,960.15.

Earnings Per Share

As for profitability, Calyxt has a trailing twelve months EPS of $-0.641.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -171.15%.

Volume

Today’s last reported volume for Calyxt is 125334 which is 93.88% below its average volume of 2049260.

Revenue Growth

Year-on-year quarterly revenue growth declined by 99.5%, now sitting on 2.06M for the twelve trailing months.

More news about Calyxt.

6. Eastside Distilling (EAST) – -10.46%

Eastside Distilling, Inc. manufactures, acquires, blends, bottles, imports, exports, markets, and sells various alcoholic beverages. The company provides rum under the brand name of Hue-Hue Coffee Rum; tequila under the Azuñia Tequila brand; vodka under the Portland Potato Vodka brand name; and whiskey under the Burnside Whiskey brand. It also offers gin and ready-to-drink products. The company sells its products on a wholesale basis to distributors in the United States. Eastside Distilling, Inc. was founded in 2008 and is headquartered in Portland, Oregon.

NASDAQ ended the session with Eastside Distilling falling 10.46% to $0.29 on Tuesday, following the last session’s downward trend. NASDAQ jumped 0.57% to $11,960.15, following the last session’s upward trend on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, Eastside Distilling has a trailing twelve months EPS of $-0.755.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -86.61%.

Volume

Today’s last reported volume for Eastside Distilling is 44530 which is 75.92% below its average volume of 184973.

Sales Growth

Eastside Distilling’s sales growth is 33% for the current quarter and 27.5% for the next.

Revenue Growth

Year-on-year quarterly revenue growth declined by 7.2%, now sitting on 14.17M for the twelve trailing months.

More news about Eastside Distilling.

7. Cocrystal Pharma (COCP) – -10.15%

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.

NASDAQ ended the session with Cocrystal Pharma dropping 10.15% to $2.44 on Tuesday, following the last session’s downward trend. NASDAQ jumped 0.57% to $11,960.15, following the last session’s upward trend on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, Cocrystal Pharma has a trailing twelve months EPS of $-0.175.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -54.07%.

Volume

Today’s last reported volume for Cocrystal Pharma is 142812 which is 183.96% above its average volume of 50293.

Yearly Top and Bottom Value

Cocrystal Pharma’s stock is valued at $2.44 at 16:32 EST, way below its 52-week high of $7.56 and way above its 52-week low of $1.74.

Moving Average

Cocrystal Pharma’s worth is under its 50-day moving average of $2.46 and way below its 200-day moving average of $3.78.

More news about Cocrystal Pharma.

8. Citius Pharmaceuticals (CTXR) – -9.29%

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

NASDAQ ended the session with Citius Pharmaceuticals dropping 9.29% to $1.27 on Tuesday while NASDAQ jumped 0.57% to $11,960.15.

Earnings Per Share

As for profitability, Citius Pharmaceuticals has a trailing twelve months EPS of $-0.202.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.83%.

Volume

Today’s last reported volume for Citius Pharmaceuticals is 1456160 which is 78.34% above its average volume of 816480.

More news about Citius Pharmaceuticals.

9. EyePoint Pharmaceuticals (EYPT) – -7.38%

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor that is in Phase 1 clinical trials for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

NASDAQ ended the session with EyePoint Pharmaceuticals falling 7.38% to $3.78 on Tuesday while NASDAQ jumped 0.57% to $11,960.15.

Earnings Per Share

As for profitability, EyePoint Pharmaceuticals has a trailing twelve months EPS of $-2.105.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -68.3%.

Sales Growth

EyePoint Pharmaceuticals’s sales growth is negative 9.9% for the current quarter and negative 15.3% for the next.

Yearly Top and Bottom Value

EyePoint Pharmaceuticals’s stock is valued at $3.78 at 16:32 EST, way under its 52-week high of $14.41 and way above its 52-week low of $2.19.

More news about EyePoint Pharmaceuticals.

10. East Resources Acquisition Company (ERESU) – -6.8%

East Resources Acquisition Company does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. East Resources Acquisition Company was founded in 2020 and is based in Boca Raton, Florida.

NASDAQ ended the session with East Resources Acquisition Company dropping 6.8% to $10.50 on Tuesday while NASDAQ jumped 0.57% to $11,960.15.

Earnings Per Share

As for profitability, East Resources Acquisition Company has a trailing twelve months EPS of $-0.16.

Yearly Top and Bottom Value

East Resources Acquisition Company’s stock is valued at $10.50 at 16:32 EST, under its 52-week high of $11.34 and above its 52-week low of $9.77.

More news about East Resources Acquisition Company.

Stay up to date with our winners and losers daily report